Advanced Psychiatric Prescribing for NPs
Master psychiatric prescribing across all major mental health disorders
Get real-world PMHNP prescribing strategies
Earn CMEs accepted by NP boards
Why NPs Choose Our Program
115 Contact Hours
1 CME = 1 contact hour, fully AANP-approved
Clinical Pearls
Real-world prescribing pearls you can use immediately
75+ Pharmacology Hours
Comprehensive pharmacology content for advanced prescribing competency
Choose Your Learning Style
Advance your nursing practice with the right learning format
Video, Audio, and Text
- Video presentations
- Audios in your podcast app
- Text summaries with key points
Multiple Products
- Video lectures
- Expert interviews
- Quick Takes: research updates
Practical Education
- Practical clinical tips and pearls
- Led by experts with real-world experience
- Free of commercial bias
Quick Take Vol. 68
What are the main benefits of long-acting injectables for women with schizophrenia? How might vitamin D impact dementia risk? What effect does lithium have on bone mineral density? How common is alcohol withdrawal syndrome? What are the long-term outcomes for patients with psychotic disorders?
Quick Take Vol. 67
How common are antidepressant discontinuation symptoms and which medications are associated with higher rates? Can Akkermansia muciniphila help manage olanzapine-induced weight gain? How does climate change impact mental health outcomes? What is the current evidence for antidrug vaccines in treating substance use disorders? Are there cognitive deficits associated with COVID-19 infection and how significant are they?
Quick Take Vol. 66
Can donanemab slow Alzheimer's progression? Does clozapine's agranulocytosis risk persist beyond the initial treatment period? Can antipsychotics cause both catatonia and neuroleptic malignant syndrome? What is the suicide risk in Parkinson's disease patients? Can AI predict antidepressant response and remission in major depression?
Quick Take Vol. 65
Can SSRIs be safely combined with oral anticoagulants? Do long-term benzodiazepine users typically escalate doses over time? Are antidepressants effective for cognitive symptoms in late-life depression? How should psychosis, agitation and depression be managed in dementia patients? Which antidepressants perform best for efficacy, tolerability and outcomes in geriatric depression?
Quick Take Vol. 64
Commentaries on papers covering hypochondriasis mortality risk, antipsychotic withdrawal syndrome, stimulant use in pregnancy, the gut-brain connection in schizophrenia, and sedative use and fall risk in the elderly.
Quick Take Vol. 63
In this volume, we explore promising developments in psychiatric treatments, including a new drug (KarXT) for schizophrenia and an antipsychotic (iloperidone) for bipolar mania. This volume also investigates the use of machine learning to predict psychosis conversion, the differentiation between substance-induced psychosis and schizophrenia, and ways to reduce racial bias in physical restraint use in emergency rooms. Do we have an unconscious bias when making decisions about using restraints?
Quick Take Vol. 62
In this Quick Take volume, we discuss a recent trial that showed a doubled risk of relapse in patients with schizophrenia when antipsychotic medication was reduced. We also touch on the use of psilocybin for treatment-resistant depression, which sounds promising—still, the need for concurrent psychotherapy and the potential long-term safety risks must be considered. Additionally, we talk about using famotidine for COVID-19–induced brain fog, real-world evidence supporting long-acting injectable antipsychotics for bipolar disorder, and effective management of poststroke depression.
Quick Take Vol. 61
In this Quick Take volume, we revisit the utilization of droperidol as a strategy for handling agitation and ponder on the discontinuation of benzodiazepines and Z-drugs among hospitalized elderly patients. Are there alternate approaches for discontinuation that could be undertaken during hospitalization? We also question the efficacy of gabapentin in treating post-COVID-19 anosmia, its possible association with neurodegenerative diseases, and whether high-dose olanzapine is a feasible treatment for resistant schizophrenia. Finally, do antidepressants influence the effectiveness of psychotherapy?
Quick Take Vol. 60
In this Quick Take volume, our faculty discuss the effectiveness of adjunctive cariprazine in the treatment of major depressive disorder with inadequate response to antidepressants and low-dose risperidone for delirium in elderly orthopedic patients. Our experts also examine the efficacy of memantine for trichotillomania and skin-picking disorder and investigate the link between psychiatric disorders and increased risk for cardiovascular disease. Finally, the real-world effectiveness of pharmacologic treatments for bipolar disorder is discussed.
Quick Take Vol. 59
In this Quick Take volume, our expert faculty investigate the link between insomnia symptoms and stroke risk, analyze the long-term effectiveness of antipsychotics in treating schizophrenia, and examine the safety of oral antipsychotics for older adults after surgery. Our experts also assess the benefits and risks of medical cannabis in Parkinson's disease treatment and explore neuroradiological abnormalities in first-episode psychosis.
Quick Take Vol. 58
In this Quick Take volume, our expert faculty examine a range of critical topics, beginning with an exploration of plasma concentrations of SSRI/SNRI post-bariatric surgery and their impact on depressive symptoms. They also investigate the potential of psychedelics as transformative therapeutics in mental health care as well as the efficacy and safety of antidepressants in patients suffering from both depression and other medical diseases. Additionally, the use of daridorexant among patients with chronic insomnia and an international research agenda focusing on clozapine-resistant schizophrenia are discussed.
Quick Take Vol. 57
In this Quick Take volume, our expert faculty examine timely research on electroconvulsive therapy as an effective adjunct for clozapine in the treatment of ultra–treatment-resistant schizophrenia, trazodone as a possible first-line treatment for insomnia, and Silexan’s potential benefits for alleviating neuropsychiatric symptoms associated with post-COVID syndrome. Our faculty also discuss studies on medication risks, such as antipsychotic drugs and the risk for acute pancreatitis as well as benzodiazepines and the risk for suicide attempt.
Quick Take Vol. 56
In this Quick Take volume, our expert faculty examine research on the possible effects of prenatal exposure to antidepressants across various trimesters of gestation as well as the safety and efficacy of lithium augmentation for the management of treatment-resistant depression. Our faculty also discuss studies regarding antipsychotics and liver safety as well as inappropriate medication use among older adults.
Quick Take Vol. 55
In this Quick Take volume, our expert faculty examine research on tobacco use and nicotine dependence among adults with psychosis, the risk of irreversible sexual dysfunction associated with SSRIs, and the effects of dual orexin receptor antagonists on delirium prevention. Our faculty also discuss sleep disorders in Parkinson’s disease and the pharmacologic treatment of obsessive-compulsive disorder.
Quick Take Vol. 54
In this Quick Take volume, our expert faculty examine research on the association between NSAIDs and reduced rates of delirium, antidepressants and apathy, and victimization and violence among patients with schizophrenia. Our women’s health expert also discusses the efficacy and safety of zuranolone on patients with postpartum depression as well as the risks of major malformations in infants after maternal exposure to benzodiazepines.
Quick Take Vol. 53
In this Quick Take volume, our expert faculty examine research on the effects of brexanolone on depressive symptoms, anxiety, and insomnia in women with postpartum depression; aripiprazole co-prescription on prolactin levels among hospitalized patients; and the use of colony-stimulating factor on the outcomes of patients undergoing clozapine rechallenge. Selected faculty experts also discuss the phenomenon of tardive syndromes and appropriate management for these as well as the effect of pharmacogenomic testing on the outcomes of major depressive disorder.
Quick Take Vol. 52
In his last Quick Take volume, Dr. James Phelps discusses selected papers on antidepressant use and withdrawal, focusing particularly on the shift from categorical to dimensional diagnostic approaches in mood disorders. He also reviews the latest CANMAT and ISBD guidelines on the management of bipolar depression and mixed states, the importance of nonmanic markers in assessing bipolar features, and implications for treatment options for bipolar depression.
Quick Take Vol. 51
In this Quick Take volume, Dr. James Phelps examines research on the use of atypical antipsychotics for various patient populations, such as patients with Parkinson’s disease psychosis, patients with poor response to clozapine, and young adults with psychotic and bipolar disorders. He also discusses systematic reviews on pharmacologic treatments for cocaine craving as well as the efficacy of dual orexin receptor antagonists for the treatment of insomnia.
Quick Take Vol. 50
In this Quick Take volume, Dr. James Phelps discusses research studies regarding haloperidol for the treatment of delirium in ICU patients, antidepressant use during pregnancy and the risk for gestational diabetes, and the risk for cardiovascular diseases associated with ADHD medications. He also tackles studies examining the associations between cannabis use and brain changes among youth as well as associations between oral contraceptives, antidepressants, and the risks for suicidal behavior and accidents among patients with premenstrual disorders.
Quick Take Vol. 49
In this Quick Take volume, Dr. James Phelps examines research studies on the effects of a smartphone-based self-management intervention for patients with bipolar disorder as well as pharmacogenetic testing on medication selection and remission among patients with major depressive disorder. He also discusses novel and emerging treatments for major depressive disorder, e-cigarette use patterns among patients attempting smoking cessation, and associations between antipsychotic use, substance use, and relapse risk in patients with schizophrenia.
Quick Take Vol. 48
In this Quick Take volume, Dr. James Phelps examines research studies on potential predictors for treatment response among various psychiatric conditions, such as baseline cognitive function for response trajectories in first-episode schizophrenia as well as C-reactive protein for SSRI response among patients with depression. He also discusses reviews on antidepressant discontinuation and the likelihood of relapse, mirtazapine as a potential augmentation strategy for clozapine-resistant schizophrenia, and the efficacy of lavender extract for the management of insomnia.
Quick Take Vol. 47
In this Quick Take volume, Dr. James Phelps examines research studies on medications with potential utility for various psychiatric conditions, such as N-acetylcysteine for schizophrenia, sublingual dexmedetomidine for acute agitation, and naltrexone–bupropion combination for binge-eating disorder. He also discusses reviews on the efficacy and safety of ketamine vs electroconvulsive therapy among patients with depression as well as knowledge gaps in the diagnosis and management of neuropsychiatric sequelae of COVID-19.
Quick Take Vol. 46
In this Quick Take volume, Dr. James Phelps discusses research studies on a novel automated intervention to extend ketamine efficacy as well as MDMA-assisted psychotherapy for posttraumatic stress disorder. He also examines studies on the possible associations between antidepressant use during pregnancy and neurodevelopmental disorders among children and SSRI dosing strategies for premenstrual syndromes. Finally, he presents recent findings on the risks for neurologic and psychiatric disorders associated with having had COVID-19 infection.
Quick Take Vol. 45
In this Quick Take volume, Dr. James Phelps examines research studies on lamotrigine and lithium combination for rapid cycling bipolar disorder, second-generation antipsychotics as adjunct treatments for major depressive disorder, and electroconvulsive therapy for the treatment of delirium. He also discusses research on microdosing with psilocybin mushrooms and the use of mood stabilizers for adjunct treatment of schizophrenia.
What Other NPs Are Saying
The content is straight to the point and easy to understand.
As someone who prefers reading, I appreciate how well-organized the content is for skimming.
The lack of commercial bias in this program gives me peace of mind.
Get Instant Access Now
Pick a membership, cancel any time.
Bronze Membership
- Up to 47 CMEs
- 12 new CMEs per year
- Unlimited downloads
- Video Lectures Treatment updates, as bite-sized videos.
- Expert Consultations Clinical pearls from interviews with experts
- Quick Takes Research summaries in adult psychiatry
- Brain Guides Practical guides for decision-making in psychopharmacology.
- Audio Feed Audio versions of our content for on-the-go learning
Silver Membership
- Up to 115 CMEs
- 30 new CMEs per year
- Unlimited downloads
- Video Lectures Treatment updates, as bite-sized videos.
- Expert Consultations Clinical pearls from interviews with experts
- Quick Takes Research summaries in adult psychiatry
- Brain Guides Practical guides for decision-making in psychopharmacology.
- Audio Feed Audio versions of our content for on-the-go learning
If you are not completely satisfied with your membership, you can contact us
within 30 days and we will issue a full refund. No questions asked.